Please assess the completion status of the following clinical trial:

Trial Title: Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 18 years and older.~* Chronic myeloid leukemia (CML)~* Previous treatment with imatinib at a dose of \>600 mg/day AND the development of progressive disease while receiving imatinib at that dose, OR~* CML with resistance to imatinib at a dose less than or equal to 600 mg/day with genetic mutation in the BCR-ABL gene that is associated with a high level of resistance to imatinib, OR~* Intolerance to imatinib at any dose~* Adequate organ function~* Women who are able to bear children must have a negative serum or urine pregnancy test. Adequate methods of contraception must be used throughout the study to avoid pregnancy for the entire interval of at least 1 month before and 3 months after completion of the study medication.~Exclusion Criteria:~* Woman who are pregnant or breastfeeding~* Men whose sexual partners are women who are of childbearing potential, and who are unwilling or unable to use an acceptable method to avoid pregnancy of his partner for the entire study period as outlined above~* Previous diagnosis of accelerated phase or blast crisis CML.~* Participants who are eligible and willing to undergo transplantation during the screening period~* Uncontrolled or significant cardiovascular disease~* Use of imatinib within 7 days.~* Use of interferon or cytarabine within 14 days~* Use of a targeted small-molecule anticancer agent within 14 days~* Use of certain medication that carry a known side effect risk of Torsade de Pointes - Certain medications that irreversibly inhibit platelet function or anticoagulants~* Prior therapy with dasatinib.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dasatinib, 70 mg twice daily (BID) (Type: EXPERIMENTAL): Dasatanib, 70 mg twice daily (BID), with dose escalation to 90 mg BID was allowed for participants who showed evidence of progression or lack of response. Up to 2 dose reductions were allowed for intolerance.

Based on this trial design, predict the completion outcome and termination type (if applicable).